Eli Lilly (NYSE: LLY) has announced results from a Phase III study of lebrikizumab, an investigational therapy designed to treat atopic dermatitis in people wit 11 March 2024
USA-based Pelage Pharmaceuticals, a clinical-stage regenerative medicine company developing treatments for hair loss, has closed a $16.75 million Series A finan 27 February 2024
Spain’s Almirall has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody, NN-8828. 19 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.